Summary
The ASCO Living Guideline for advanced non-small cell lung cancer (NSCLC) with driver alterations has gotten its first update, with data from recent studies.
New Treatment Options for Stage IV NSCLC With Driver Alterations
The ASCO Living Guideline for advanced non-small cell lung cancer (NSCLC) with driver alterations has gotten its first update, with data from recent studies — DESTINY-Lung01 and CodeBreaK100 — incorporated into the guidance.
In the update, published in the Journal of Clinical Oncology, Dwight H. Owen, MD, MS, of the Ohio State University in Columbus, and colleagues recommended that for pretreated patients with advanced NSCLC and an activating HER2 (ERBB2) mutation, moving on to monotherapy with trastuzumab deruxtecan (Enhertu) is an option, per DESTINY-Lung01 findings. And in previously treated patients with advanced NSCLC and a KRAS G12C mutation, monotherapy with sotorasib (Lumakras) is on the table based on CodeBreaK100 findings.
DESTINY-Lung01 results were presented at the 2021 European Society of Medical Oncology (ESMO) meeting, while CodeBreaK100 findings were shared at the 2022 American Association for Cancer Research (AACR) meeting. Multiple experts at the time offered their take on the value of the findings via VJ Oncology.
